DEAL ANNOUNCEMENT / PRESS RELEASE
October 3, 2025
Read time: 3 min
McDermott Will & Schulte advised Servier, an international, independent pharmaceutical group governed by a foundation, on the acquisition from BioNova of BN104, a menin inhibitor with “best-in-class” potential currently in phase 1/2 development for the treatment of acute leukemia.
Servier intends to accelerate the global clinical development of BN104 for the treatment of acute myeloid leukemia, where there are significant unmet medical needs, particularly for the development of safer therapies in cases of relapse or resistance to treatment.
This drug candidate will enable Servier to expand its hematological oncology franchise and strengthen its leadership with a targeted and differentiated portfolio of drugs in this field.
The Servier legal team consisted of:
- Shurong Qu: Senior Legal Counsel, Global BD and R&D
- Manon Fouques: Senior Legal Counsel, Global BD and R&D
- Nicolas Mavel: Director, Global BD and R&D Legal Affairs
The McDermott Will & Schulte Paris team consisted of:
- Emmanuelle Trombe, Life Sciences Partner
- Ludivine Rabreau, Life Sciences Associate
- Nejma Palasse, Life Sciences Associate
- Romain Desmonts, Tax Partner
The McDermott Will & Schulte team in the United States consisted of:
- Eric M. Preston, Partner – Chicago
- Todd Hudson, Partner – Nashville
- Jon Dubrow, Partner – Washington
- Timothy (Ty) Carson, Counsel – Washington
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.
